CHP1 and proximal spinal muscular atrophy: In SMA model mice treated with SMN-based ASOs, CHP1 reduction prolonged survival, improved electrophysiological defects, NMJ growth and maturation, and muscle fiber size in comparison to the effects of ASOs alone.